logo
logo

ScopeBio raises €6 million in seed funding for smart DNA CRISPR tests, backed by SHIFT Invest and Oost NL.

Jun 16, 2025•about 1 month ago

Amount Raised

€6 Million

Round Type

seed

WageningenBiotechnology

Investors

Oost NlShift Invest

Description

Scope Biosciences, a spin-off from Wageningen University & Research, has secured an investment from SHIFT Invest and Oost NL. This funding marks a significant step for the company following its first commercial traction. The funds will help advance their CRISPR-based diagnostic platform, scopeDx®. It aims to improve diagnostics in agriculture and healthcare.

Company Information

Company

Scope Biosciences

Location

Wageningen, Gelderland, Netherlands

About

Scope Biosciences is a spin-off from Wageningen University & Research focused on developing the scopeDx® CRISPR-based diagnostic platform. This technology allows for ultra-precise DNA detection without the need for special equipment or labs, enabling diagnostics closer to the source in agriculture and healthcare. It aims to improve crop disease detection and provide reliable testing in areas lacking centralized laboratories.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Related People